Skeletal disorders

United States Topical Pain Relief Market Report 2021: $3.27 Billion Market by by Therapeutic Class, Formulation, Type and Distribution Channel to 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 2, 2021
Health, Pharmaceutical, Medicine, Pain, Branches of biology, Rheumatology, Acute pain, Skeletal disorders, Palliative care, Analgesic, Pain management, Arthritis, Arthralgia, Topical medication

The "U.S. Topical Pain Relief Market by Therapeutic Class, Formulation, Type and Distribution Channel: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Topical Pain Relief Market by Therapeutic Class, Formulation, Type and Distribution Channel: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • Whenever these analgesics are applied directly to the skin they are known as topical pain relief medications.
  • Increase in prevalence of arthritis and joint pain is the major factor that contributes toward the growth of the topical pain relief market in the U.S.
  • The U.S. topical pain relief market is segmented into therapeutic class, type, formulation, and distribution channel.

New Invention Stops or Delays the Progression of Osteoarthritis of the Knee

Retrieved on: 
Thursday, April 1, 2021
Medical specialties, Surgery, Clinical medicine, Skeletal disorders, Arthritis, Aging-associated diseases, Rheumatology, Prosthetics, Osteoarthritis, Joint replacement, Orthopedic surgery, Knee

NEW YORK, April 1, 2021 /PRNewswire/ --New York Bone & Joint Specialists is at the forefront of orthopedic technology, with an exciting invention focused on preventing the development and/or progression of osteoarthritis of the knee.

Key Points: 
  • NEW YORK, April 1, 2021 /PRNewswire/ --New York Bone & Joint Specialists is at the forefront of orthopedic technology, with an exciting invention focused on preventing the development and/or progression of osteoarthritis of the knee.
  • At the same time, this invention can be used to promote and accelerate healing of any orthopedically repaired tissue.
  • As a result, the device would diminish the need for joint replacement surgery, and save billions of dollars in medical costs.
  • "Millions of people suffer from knee osteoarthritis and millions undergo extensive joint replacement therapy," says Dr. Popovitz.

Non-surgical treatment quickly reduces arthritis knee pain and improves function

Retrieved on: 
Monday, March 22, 2021
Branches of biology, Clinical medicine, Musculoskeletal system, Acute pain, Skeletal disorders, Aging-associated diseases, Rheumatology, Arthritis, Genicular artery, Pain, Knee, Osteochondritis dissecans

Genicular artery embolization (GAE) reduces inflammation in the knee to improve function and quality of life for people with moderate to severe knee pain.

Key Points: 
  • Genicular artery embolization (GAE) reduces inflammation in the knee to improve function and quality of life for people with moderate to severe knee pain.
  • "Prior to treatment, patients' knee pain had taken over their whole life," said Siddharth A. Padia, MD, FSIR, professor of radiology, UCLA Health, and lead researcher of the study.
  • Until recently, arthritis pain was regarded as a "wear-and-tear" disease, but as the cartilage breaks down it releases enzymes that can cause inflammation and pain, and limit functioning.
  • While it quickly improves patients' pain, even more exciting is that the pain relief is durablelasting for at least 12 months.

Morris Animal Foundation Partners with Elanco to Improve Understanding of Canine Osteoarthritis

Retrieved on: 
Friday, March 19, 2021
Skeletal disorders, Medical specialties, Medicine, Health, Elanco, Eli Lilly and Company, Aging-associated diseases, Rheumatology, Arthritis, Osteoarthritis, Dog, Labrador Retriever

DENVER, March 19, 2021 /PRNewswire/ --Morris Animal Foundation, a leader in advancing animal health, is partnering with Elanco Animal Health Incorporated (NYSE: ELAN) to better understand the incidence and prevalence of osteoarthritis (OA) in dogs using data generated by the Foundation's Golden Retriever Lifetime Study .

Key Points: 
  • DENVER, March 19, 2021 /PRNewswire/ --Morris Animal Foundation, a leader in advancing animal health, is partnering with Elanco Animal Health Incorporated (NYSE: ELAN) to better understand the incidence and prevalence of osteoarthritis (OA) in dogs using data generated by the Foundation's Golden Retriever Lifetime Study .
  • "This is an important issue in canine health, and we are excited to be partnering with Elanco Animal Health to better understand osteoarthritis and improve treatment of this debilitating condition," said Tiffany Grunert, President and CEO of Morris Animal Foundation.
  • Elanco is sponsoring a new section of the owner and veterinarian questionnaires that directly evaluates signs of osteoarthritis.
  • Elanco's sections include the Canine Osteoarthritis Staging Tool (COAST) and Liverpool Osteoarthritis in Dogs Index (LOAD) tools that help in the diagnosis of the disease.

$2 Billion Cold Pain Therapy Markets, 2025 - OTC [Gels, Creams, Patches, Wraps, Pads] & Prescription Devices [Motorized, Non-Motorized] - ResearchAndMarkets.com

Retrieved on: 
Friday, March 12, 2021
Health, Pharmaceutical, Pain, Clinical medicine, Medicine, Acute pain, Rheumatology, Skeletal disorders, Nociception, Arthritis, Pain management

The global cold pain therapy market is projected to reach USD 2 billion by 2025 from USD 1.6 billion in 2020, at a CAGR of 4.4% during the forecast period.

Key Points: 
  • The global cold pain therapy market is projected to reach USD 2 billion by 2025 from USD 1.6 billion in 2020, at a CAGR of 4.4% during the forecast period.
  • Factors such as increasing prevalence of arthritis and the rising number of sports injuries are the key factors boosting the demand for cold pain therapy products for the management of pain.
  • The musculoskeletal disorders segment accounted for the largest share of the cold pain therapy market, by application, in 2020
    The lateral flow assays segment accounted for the largest share of the cold pain therapy market in 2020.
  • The cold pain therapy market is segmented into five major regions, namely, North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS™ (PTP-001) for the Treatment of Knee OA

Retrieved on: 
Thursday, March 11, 2021
Medical specialties, Skeletal disorders, Medicine, Clinical medicine, Glycosaminoglycans, Arthritis, Rheumatology, Osteoarthritis, Aging-associated diseases, Injection, Hyaluronic acid, Sodium hyaluronate

The study is evaluating the safety and efficacy of MOTYS (PTP-001) to treat osteoarthritis (OA) of the knee.

Key Points: 
  • The study is evaluating the safety and efficacy of MOTYS (PTP-001) to treat osteoarthritis (OA) of the knee.
  • Current treatments for knee OA are limited to corticosteroids and hyaluronic acid (HA) injections.
  • Bioventus, the Bioventus logo and DUROLANE are registered trademarks and Bioventus, MOTYS and GELSYN-3 are trademarks of Bioventus LLC.
  • Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site.

Zoetis Receives European Commission Marketing Authorization for Solensia® (frunevetmab), a New Therapy for Feline Osteoarthritis Pain

Retrieved on: 
Monday, February 22, 2021
Biotechnology, Health, Veterinary, Pharmaceutical, Clinical trials, Nervous system, Branches of biology, Symptoms and signs, Acute pain, Arthritis, Skeletal disorders, ZTS, Feline, Cat, Pain, Osteoarthritis, Solensia, Zoetis

Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia (frunevetmab), a new feline osteoarthritis treatment to alleviate pain.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia (frunevetmab), a new feline osteoarthritis treatment to alleviate pain.
  • OA pain in cats remains vastly undertreated, and Solensia is a prime example of our commitment to meaningful innovation in feline medicines.
  • By alleviating pain, Solensia helps generally improve physical activity level, sociability and quality of life of cats with OA.
  • A total of 76% of cat owners reported sustained improvement in signs of pain when their cats were treated with Solensia.

OM1 Artifical Intelligence (AI) Shared Decision Aid Demonstrates Significant Improvement In Decision Quality And Surgical Outcomes For Knee Osteoarthritis

Retrieved on: 
Thursday, February 18, 2021
Medical specialties, Clinical medicine, Medicine, Skeletal disorders, Prosthetics, Aging-associated diseases, Rheumatology, Arthritis, Osteoarthritis, Knee replacement, Hip replacement, TKR

In the U.S., more than 30 million adults live with painful, immobilizing joint pain due to osteoarthritis, and more than one million total knee (TKR) and hip replacement (THR) surgeries are performed yearly.

Key Points: 
  • In the U.S., more than 30 million adults live with painful, immobilizing joint pain due to osteoarthritis, and more than one million total knee (TKR) and hip replacement (THR) surgeries are performed yearly.
  • The treatment of musculoskeletal conditions in general, and osteoarthritis in particular, is characterized by a high health resource burden and substantial variability in choice of treatment and outcomes.
  • The randomized clinical trial (RCT) examined the impact of the OM1 Joint Insights tool, an artificial intelligence (AI)-enabled decision aid, including patient education, preference assessment, and personalized predictions of clinical outcomes compared to education only on decision quality, patient satisfaction, and functional outcomes among individuals with knee OA considering total knee replacement (TKR).
  • "Advances in applying AI technologies to robust clinical data are enabling rapid advancement in generating personalized outcomes information," said Dr. Richard Gliklich, CEO of OM1.

Water Cycling Reduces Osteoarthritis Pain in Knees

Retrieved on: 
Monday, February 15, 2021
Skeletal disorders, Medical specialties, Clinical medicine, Health, Rheumatology, Arthritis, Aging-associated diseases, Osteoarthritis, Cycling, Knee arthritis

In addition to our water bikes, we also use water trampolines and water treadmills to help people with osteoarthritis of the knees, hips, and back."

Key Points: 
  • In addition to our water bikes, we also use water trampolines and water treadmills to help people with osteoarthritis of the knees, hips, and back."
  • According to this study https://www.eqoljournal.com/wp-content/uploads/2020/12/Khanjari-et-al.-2... the results show that jogging type exercise in water has a beneficial effect on reducing the symptoms of osteoarthritis of the knee.
  • 12 weeks of water cycling (twice a week for 45 minutes per session) had a positive effect on reducing pain and improving function in the elderly with osteoarthritis of the knee.
  • No-one else has the variety and quality of water exercise equipment to help their customers gain the benefits of working out in water.

US Rheumatoid Arthritis Drug Market Patent Price Insight Report 2026

Retrieved on: 
Monday, February 15, 2021
Medical specialties, Clinical medicine, Medicine, Rheumatology, Autoimmune diseases, Connective tissue diseases, Skeletal disorders, Arthritis, Rheumatoid arthritis, Sjögren syndrome, Rheumatoid nodule, Adalimumab

NEW DELHI, Feb. 15, 2021 /PRNewswire/ -- "US Rheumatoid Arthritis Drug Market, Dosage, Price, Sales Insight 2021 - 2026".

Key Points: 
  • NEW DELHI, Feb. 15, 2021 /PRNewswire/ -- "US Rheumatoid Arthritis Drug Market, Dosage, Price, Sales Insight 2021 - 2026".
  • Rheumatoid arthritis is a type of autoimmune arthritis, which has an incidence rate of about 41 per 100,000 populations of US.
  • About 130,000 newly diagnosed cases of rheumatoid arthritis is observed every year in US and about 1.5 Million people are living with rheumatoid arthritis in US during year 2020.
  • "Report Offers Comprehensive Insight On Dosage, Patent, Price & Sales Insight On All Approved Drugs In The US Rheumatoid Arthritis Drug Market"
    The rise in prevalence of rheumatoid arthritis increases the demand of rheumatoid arthritis drugs in the market.